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Abstract
Summary The final analysis of this 2-year, randomized,
crossover study showed that postmenopausal women with
osteoporosis were more adherent, compliant, and persistent
withsubcutaneous denosumab injections every 6 months than
with once-weekly alendronate tablets. After receiving both
treatments, women reported greater satisfaction with inject-
able denosumab and preferred it over oral alendronate.
Introduction Osteoporosis patients who are non-compliant
or non-persistent with therapy may have suboptimal clinical
outcomes. This 2-year, randomized, open-label, crossover
study compared treatment adherence between subcutaneous
denosumab, 60 mg every 6 months, and oral alendronate,
70 mg once weekly.
Methods Postmenopausal women at 25 centers in the USA and
Canada with bone mineral density T-scores −4.0 to −2.0 and no
prior bisphosphonate use received alendronate then denosumab,
or denosumab then alendronate, over successive 12-month
periods. Adherence required both compliance (denosumab
injections 6 months apart or ≥80% of alendronate tablets) and
persistence (both denosumab injections or ≥2 alendronate doses
in the last month and completion of the treatment period).
Results Of the 250 women enrolled (124 alendronate, 126
denosumab), 221 entered the second year (106 denosumab,
115 alendronate). Denosumab was associated with less non-
adherence than alendronate (first year, 11.9% vs 23.4%;
second year, 7.5% vs 36.5%). Risk ratios for non-adherence,
non-compliance, and non-persistence favored denosumab in
both years (p<0.05). Of 198 subjects expressing treatment
preference, 183 (92.4%) preferred the injections over the oral
therapy. BMD improved further when subjects received
denosumab after alendronate and remained stable when they
received alendronate after denosumab.
Conclusion Based on the final results of this crossover study
after women had received each treatment for up to 1 year,
postmenopausal women with osteoporosis were more adher-
ent, compliant, and persistent with subcutaneous denosumab
injections every 6 months than with once-weekly alendronate
tablets and reported increased treatment preference and
satisfaction with injectable denosumab over oral alendronate.
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Oral bisphosphonates are the most commonly prescribed
osteoporosis medications and effectively reduce fracture
risk among patients with osteoporosis. However, several
large studies have reported that the majority of postmeno-
pausal women discontinue bisphosphonate therapy within
1 year of initiation [1–3]. Persistence, compliance, and
adherence to long-term bisphosphonate treatment are often
inadequate, leading to suboptimal health outcomes [3–7],
including increased risk of fracture [1]. Treatment adher-
ence among patients with chronic conditions may be
influenced by many factors, including patient beliefs,
preferences, and satisfaction with the prescribed treatment
[8–14].
Denosumab is a human monoclonal antibody with
affinity and specificity for RANK ligand, thereby inhibiting
osteoclast formation, function, and survival [15]. A single
subcutaneous injection of denosumab, 60 mg (Prolia
®), has
been shown to increase bone mineral density (BMD) and
decrease bone turnover markers for at least 6 months [16].
In clinical trials, subcutaneous denosumab once every
6 months was well tolerated, increased BMD [17–19], and
significantly reduced fracture risk [20]. Denosumab was
also associated with significantly greater increases in BMD
at the femoral neck, trochanter, lumbar spine, and one-third
radius compared with once-weekly oral alendronate treatment
[19].
The Denosumab Adherence Preference Satisfaction
(DAPS) study evaluated adherence (including both compli-
ance and persistence) to 12 months of treatment with
subcutaneous denosumab, 60 mg every 6 months, and
12 months of treatment with oral alendronate, 70 mg once
weekly, using a randomized, crossover design. This enabled
evaluation of the primary efficacy endpoint of adherence
during the first year, as reported previously [21], as well as
adherence, compliance, persistence, patient beliefs, prefer-
ence, satisfaction, and bother after subjects received both
treatments. In addition, the crossover design provided
information about the effect of administration sequence on
adherence to denosumab and alendronate. This report
presents the final results from both years of the DAPS
study.
Methods
Study design
Eligible subjects were randomized in a 1:1 allocation to one
of two treatment sequences—denosumab/alendronate or
alendronate/denosumab—and received each treatment for
1 year. All study treatments were administered open label.
One group of subjects received oral alendronate, 70 mg
once weekly, in the first year, and then crossed over to
subcutaneous denosumab, 60 mg every 6 months, in the
second year (given on day 1 and month 6 of the second
year). The other group received the same treatments, but in
reverse order. Subjects who terminated treatment before the
end of the first year of study but who agreed to therapy in
the second year were allowed to cross over treatment and
enter the second year early.
Eligibility criteria
This multicenter, randomized, open-label, crossover study
was conducted at 20 centers in the USA and 5 centers in
Canada between October 2007 and July 2010 (Appendix).
Subjects enrolled were ambulatory, postmenopausal wom-
en, aged 55 years or older, with baseline BMD T-scores
between −4.0 and −2.0 at the lumbar spine, total hip, or
femoral neck as measured by dual energy X-ray absorpti-
ometry. Key exclusion criteria were prior bisphosphonate or
denosumab treatment, use of bone-active drugs, vitamin D
deficiency (<20 ng/mL [49.9 nmol/L]), or contraindications
to alendronate treatment. The study was conducted in
accordance with the ethical principles of the Declaration
of Helsinki. Informed consent was obtained for each
subject, and an institutional review board or independent
ethics committee approved the study protocol for each site.
Treatment
Study clinic personnel administered denosumab as a
subcutaneous injection. Alendronate was dispensed in a
bottle with a medication event monitoring system (MEMS)
cap to monitor administration times and dates. Subjects
were informed that the way in which they took alendronate
tablets would be monitored. They were instructed to open
the bottle only when taking medication and only remove
one tablet at each opening. They were also instructed to
follow the label dosing instructions for alendronate (ingestion
on the same morning each week and avoiding lying down,
eating,ordrinkingforatleast30minafteradministration).All
subjects received daily supplementation of calcium
(1,000 mg) and vitamin D (at least 400 IU).
Outcomes
Adherence was defined as a composite of being both
compliant and persistent with therapy. For denosumab,
subjects were considered compliant if they received the two
denosumab injections 6 months±4 weeks apart; they were
considered persistent if they received both injections and
completed that treatment period within the study-defined
time span. For alendronate, subjects were considered
318 Osteoporos Int (2012) 23:317–326compliant if they took at least 80% of the once-weekly
tablets; they were considered persistent if they took at least
two tablets in the last month and completed that treatment
period within the allotted time. Adherence to alendronate
administration was based on MEMS data and counted a
maximum of four events (i.e., consumption of four
alendronate tablets) per 28-day period. The cutoff of 80%
for compliance to alendronate was similar to that used in
previous bisphosphonate studies [1, 2, 7]. Patients with
>80% compliance to bisphosphonate therapy have a 16%
lower relative risk of fracture than patients who are less
compliant [5]. Subjects who took at least two of four tablets
in the last month were considered persistent to alendronate
because it was assumed that some non-persistent subjects
might take study treatment when they realized that the 12-
month follow-up visit was approaching.
At each follow-up visit, subjects completed an adapta-
tion of the Beliefs about Medicines Questionnaire (BMQ)
[22] that included 22 specific questions in the following
major domains: the necessity of the prescribed medication
to manage osteoporosis now and in the future (five items),
concerns about the potential adverse effects of taking the
prescribed medication to manage osteoporosis (ten items),
and preference for one medication over the other (seven
items). At each visit, subjects also completed the Preference
Satisfaction Questionnaire (PSQ) [23], which measured five
domains: preference, pill satisfaction, injection satisfaction,
pill bother, and injection bother.
BMD (lumbar spine and hip) was assessed at baseline and
the 12-month visits of each year. Fasting serum C-telopeptide
(CTX-1) and N-terminal propeptide type I procollagen
(P1NP) were assessed at baseline and 12 months of the first
year, and 6 and 12 months after crossover.
Statistical methods
The primary endpoint was the proportion of subjects in
each treatment group who were adherent to treatment at the
end of the first year. Efficacy analyses used the intent-to-
treat principle and included all randomized subjects for the
first year, and all crossover subjects for the second year.
Data from both years are reported in this analysis because
data that were missing at the time of the prior report [21]
could be collected during the second year. Exploratory
analyses of BMD and BMQ included all observed data at
the time point of interest.
Safety endpoints included subject incidences of adverse
events and serious adverse events. The safety population
within each year of study included all subjects who
received at least one dose of study medication in that year.
If a subject accidentally received both study treatments in a
single period, they were considered to have received
denosumab for safety analyses in that period.
Statistical hypothesis tests were conducted at the 0.05
significance level. Point estimates and 95% confidence
intervals (CI) were determined for the absolute rate
reduction and for the rate ratio between treatment groups
for non-adherence, non-compliance, and non-persistence.
These endpoints were compared between treatment groups
using a Cochran–Mantel–Haenszel test stratified by center
and prior osteoporotic fracture. Ordinal, categorical,
patient-reported endpoints were compared between treat-
ment groups in each treatment period using a van Elteren
non-parametric test, stratified by investigational site and
prior osteoporotic fracture. Treatment-by-period interac-
tions were assessed for significance (p value<0.1) by
statistical methods with data from both treatment periods.
Time to non-adherence was defined as the time to treatment
non-compliance or non-persistence, whichever occurred
earliest. Non-adherence to alendronate could begin at any
time. The time to denosumab non-adherence (for non-
adherent subjects) was defined as 6 months and 4 weeks
after the most recent injection. Time to treatment non-
adherence was described with Kaplan–Meier methods
without statistical comparisons.
Logistic regression analyses of non-adherence, non-
compliance, and non-persistence were stratified by prior
osteoporotic fracture. Potential explanatory variables ex-
plored individually in the model were baseline values (i.e.,
prior to study entry) for age, age group (<65 or ≥65 years),
race (Caucasian or non-Caucasian), prior bone-loss therapy,
parental hip fracture (yes or no), smoking history, alcohol
intake, and time since menopause, as well as values from
the start of each treatment period for total hip BMD and
BMQ scores. The sample size was determined as described
previously [21].
Results
Study participants
Of the 250 subjects who were originally enrolled, 221
entered the second year of treatment (106 denosumab,
115 alendronate) (Fig. 1). Baseline characteristics prior to
study treatment were similar between treatment groups
(Table 1).
Adherence
Adherence is summarized by study year in Table 2.B e c a u s e
the sequence effect (treatment-by-period interaction) was
significant (p value<0.1), adherence, compliance, and
persistence were reported separately for each treatment
period rather than combining data from both treatment
periods.
Osteoporos Int (2012) 23:317–326 319By the end of the first 12 months, 11.9% subjects were
non-adherent to denosumab, and 23.4% were non-adherent
to alendronate, for an absolute difference of 10.5% (95% CI
1.3%, 19.7%) adjusting for investigational site and prior
osteoporosis fracture status. The rate ratio for non-
adherence in the first year was 0.54 (95% CI 0.31, 0.93;
p=0.026) between treatment groups, representing a 46%
reduction in the risk of non-adherence for denosumab
compared with alendronate. The non-adherence rate after
crossover was 7.5% for denosumab and 36.5% for
alendronate, with an absolute difference of 30.9% (95%
CI 20.6%, 41.3%). The adjusted non-adherence ratio after
crossover was 0.20 (95% CI 0.10, 0.41; p<0.001),
representing an 80% lower risk of non-adherence with
denosumab. Time to treatment non-adherence (Fig. 2)
differed early between treatments and was more pro-
nounced after crossover.
Compliance and persistence
Results of the analyses of non-compliance and non-
persistence (Table 2) were consistent with the analyses of
non-adherence for each year. Non-compliance results for
the first year did not change from the previous report with
the addition of new data that had been missing at the time
of reporting the primary endpoint [21]. Non-compliance
Table 1 Baseline demographics and disease characteristics (efficacy populations)
First year of study Second year of study
Receiving
alendronate (n=124)
Receiving
denosumab (n=126)
Receiving
alendronate (n=115)
Receiving
denosumab (n=106)
Sex, female, n (%) 124 (100) 126 (100) 115 (100) 106 (100)
Ethnicity/race, n (%)
White or Caucasian 119 (96.0) 115 (91.3) 107 (93.0) 102 (96.2)
Hispanic or Latino 1 (0.8) 6 (4.8) 4 (3.5) 1 (0.9)
Black or African American 2 (1.6) 2 (1.6) 1 (0.9) 1 (0.9)
Other 2 (1.6) 3 (2.4) 3 (2.6) 2 (1.9)
Age, years, mean (SD) 65.3 (7.7) 65.1 (7.6) 65.1 (7.4) 65.3 (7.4)
Years since menopause, mean (SD) 17.2 (10.0) 18.2 (11.4) 17.9 (10.9) 17.0 (9.7)
BMD T-scores at year baseline, mean (SD)
Lumbar spine −1.89 (1.13) −2.04 (1.16) −1.61 (1.29) −1.44 (1.15)
Total hip −1.60 (0.76) −1.60 (0.74) −1.38 (0.74) −1.40 (0.73)
Femoral neck −2.03 (0.62) −2.01 (0.55) −1.84 (0.60) −1.90 (0.63)
Values are given for baseline (start of the first year)
SD standard deviation, BMD bone mineral density
Alendronate/denosumab sequence Denosumab/alendronate sequence
Year 1 (alendronate)
Efficacy population 124
Safety population 118
Completed first year 106
Early crossover 1
Early termination 17
Adverse event 5
Lost to follow-up 5
Consent withdrawn 4
Ineligibility determined 2
Administrative decision 1
Year 1 (denosumab)
Efficacy population 126
Safety population 125
Completed first year 114
Early crossover 3
Early termination 9
Consent withdrawn 6
Lost to follow-up 3
Randomized 250
Year 2 (denosumab)
Efficacy population 106
Safety population 106
Completed second year 103
Discontinued before end of second year 3
Adverse event 1
Complete out of scheduled visit window 1
Noncompliance 1
Year 2 (alendronate)
Efficacy population 115
Safety population 110
Completed second year 95
Discontinued before end of second year 20
Consent withdrawn 8
Adverse event 7
Complete out of scheduled visit window 2
Noncompliance 2
Protocol-specified criteria deviation 1
Fig. 1 Subject disposition.
Note: One subject received both
study treatments in a single
period and was considered to
have received denosumab for
safety analyses in that period.
The safety population included
all subjects who received at least
one dose of study medication;
subjects in the alendronate
group were required to return at
least one MEMS bottle to con-
firm they had received at least
one dose of alendronate. Sub-
jects were considered to have
completed the period/year if the
year's month 12 visit occurred
within or later than the schedule
visit window with “Yes” for the
end-of-year completion response
320 Osteoporos Int (2012) 23:317–326after crossover was 6.6% for denosumab and 32.2% for
alendronate, with an absolute difference of 27.7% (95% CI
17.6%, 37.7%); the adjusted rate ratio was 0.20 (95% CI
0.09, 0.43; p<0.001), representing an 80% relative risk
reduction of non-compliance with denosumab.
Non-persistence in the first year was 9.5% for denosu-
mab and 20.2% for alendronate, with an absolute difference
of 9.8% (95% CI 1.1%, 18.5%); the adjusted rate ratio was
0.50 (95% CI 0.27, 0.93; p=0.029), representing a 50%
relative risk reduction of non-persistence with denosumab.
Non-persistence after crossover was 2.8% for denosumab
and 28.7% for alendronate, with an absolute difference of
27.4% (95% CI 18.1%, 36.7%); the adjusted rate ratio was
0.09 (95% CI 0.03, 0.30; p<0.001), representing a 91%
relative risk reduction of non-persistence with denosumab.
Patient-reported outcomes
Figure 3 summarizes BMQ scores at each study visit. Mean
scores for subject beliefs about the necessity for the
prescribed treatment were greater for denosumab than for
alendronate at the 6-month visit in the first year (p=0.022),
Table 2 Subject non-adherence, non-compliance, and non-persistence (efficacy populations)
Crude rate, n (%) Absolute rate
a reduction Rate ratio
a p value
a
Denosumab Alendronate (95% CI) (95% CI)
First year (n=126) (n=124)
Adherence
b 111 (88.1) 95 (76.6)
Non-adherence 15 (11.9) 29 (23.4) 10.5 (1.3, 19.7) 0.54 (0.31, 0.93) 0.026
Compliance
c 114 (90.5) 97 (78.2)
Non-compliance 12 (9.5) 27 (21.8) 11.0 (2.2, 19.7) 0.48 (0.26, 0.87) 0.014
Persistence
d 114 (90.5) 99 (79.8)
Non-persistence 12 (9.5) 25 (20.2) 9.8 (1.1, 18.5) 0.50 (0.27, 0.93) 0.029
Second year (n=106) (n=115)
Adherence
b 98 (92.5) 73 (63.5)
Non-adherence 8 (7.5) 42 (36.5) 30.9 (20.6, 41.3) 0.20 (0.10, 0.41) <0.001
Compliance
c 99 (93.4) 78 (67.8)
Non-compliance 7 (6.6) 37 (32.2) 27.7 (17.6, 37.7) 0.20 (0.09, 0.43) <0.001
Persistence
d 103 (97.2) 82 (71.3)
Non-persistence 3 (2.8) 33 (28.7) 27.4 (18.1, 36.7) 0.09 (0.03, 0.30) <0.001
aBased on the Cochran–Mantel–Haenszel method stratified by center and prior osteoporotic fracture
bAdherence was defined as satisfying the criteria for both compliance and persistence
cCompliance was defined as receiving two injections 6 months±4 weeks apart (denosumab) or at least 80% of weekly doses (alendronate)
dPersistence was defined as receiving either two injections total (denosumab) or at least two weekly doses in the last month (alendronate), and
completing the year of treatment within the allotted time (both groups)
Fig. 2 Time to treatment non-
adherence. Non-adherence to
alendronate could begin at
any time, and the time to
non-adherence was defined
as the time to treatment non-
compliance or time to treatment
non-persistence, whichever
occurred earliest. The time to
denosumab non-adherence for
non-adherent subjects was de-
fined as 6 months and 4 weeks
after the most recent injection.
For each treatment group, time
points with >95% cumulated
subjects were excluded Alendronate
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Osteoporos Int (2012) 23:317–326 321but not at the other visits. Mean scores for subject concerns
about potential adverse consequences of treatment were
lower for denosumab than for alendronate at the 6-
month (p=0.010) and 12-month (p=0.028) visits after
crossover, but not at the other time points. Mean scores for
subject preference for one medication over the other were
greater for denosumab than for alendronate at every visit
(all p<0.001).
At the end of study, of the 198 subjects who expressed a
preference between treatments, 183 (92.4%) preferred
subcutaneous denosumab injections over alendronate tablets
(p<0.001) (Online resource 1). Of the 204 subjects who
expressed a preference between treatments for the long term,
186 (91.2%) said they would choose denosumab injections
for long-term treatment (p<0.001) (Online resource 1).
Figure 4 summarizes PSQ subject satisfaction scores at
the end of each treatment period. Regardless of the
treatment sequence, a greater proportion of subjects
reported they were quite/very satisfied with frequency of
administration, mode of administration, and convenience of
denosumab compared with alendronate.
Logistic regression analyses of non-adherence
Analyses of non-adherence based on multiple logistic
regressions indicated that the only significant subject charac-
teristic in the first year was total hip BMD (p=0.028) (Online
resource 2). Significant subject characteristics after crossover
were BMQ scores for necessity (p=0.006), concern (p=
0.025), and preference (p=0.024).
Exploratory endpoints: bone mineral density and bone
turnover markers
Mean percentage changes in BMD (observed data) in the
first year for the alendronate and denosumab groups,
respectively, were as follows: lumbar spine, 4.9% (n=93)
and 5.6% (n=93); total hip, 2.5% (n=102) and 3.2% (n=
109); and femoral neck, 2.0% (n=102) and 3.1% (n=109).
Mean percentage BMD changes from baseline of the
second year to the end of treatment for alendronate and
denosumab, respectively, were as follows: lumbar spine,
0.6% (n=82) and 2.9% (n=92); total hip, 0.4% (n=92) and
1.5% (n=102); and femoral neck, −0.1% (n=92) and 1.7%
(n=102).
Median CTX-1 levels at baseline, the end of the first
year, and the end of treatment, respectively, were as
follows: denosumab/alendronate sequence, 0.465 ng/mL
(n=75), 0.139 ng/mL (n=108), and 0.223 ng/mL (n=92);
alendronate/denosumab sequence, 0.435 ng/mL (n=81),
0.132 ng/mL (n=100), and 0.140 ng/mL (n=100). Median
values for P1NP levels at baseline, the end of the first year,
and the end of treatment, respectively, were as follows:
denosumab/alendronate sequence, 50.06 μg/L (n=75),
14.97 μg/L (n=108), and 21.73 μg/L (n=92); alendronate/
denosumab sequence, 53.37 μg/L (n=81), 17.26 μg/L
(n=100), and 16.96 μg/L (n=100).
At baseline, no subject in either treatment group had a
CTX-1 level below the limit of quantification. At the end of
the first year, 2/108 (1.9%) subjects in the denosumab
group and 3/100 (3.0%) subjects in the alendronate group
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322 Osteoporos Int (2012) 23:317–326had undetectable CTX-1 levels. Six months after crossover,
13/86 (15.1%) subjects in the denosumab group and 4/97
(4.1%) subjects in the alendronate group had undetectable
CTX-1 levels. At the end of study, 15/100 (15.0%) subjects
in the denosumab group and 6/92 (6.5%) subjects in the
alendronate group had undetectable CTX-1 levels.
Safety
The safety population included 228 subjects who received
at least one dose of alendronate and 230 subjects who
received at least one dose of denosumab. Adverse events
with incidence rates >2% by preferred term in either
treatment group were not significantly different between
treatment groups in the second treatment period. Overall,
63.2% and 65.7% of subjects reported at least one adverse
event during alendronate and denosumab treatment, respec-
tively. Adverse events reported by at least 5% of subjects
during either treatment (alendronate, denosumab) were
arthralgia (6.6%, 6.1%), pain in extremity (3.9%, 6.1%),
and back pain (5.7%, 3.9%).
Adverse events of fracture during the first year included
one subject with fibula fracture during alendronate treatment
and one with foot fracture during denosumab treatment.
Adverse events of fracture after crossover included one
subject with humerus fracture during alendronate treatment
andone subject eachwithfoot,pubis,andulnafractureduring
denosumab treatment.
Serious adverse events occurred in 3.9% and 3.5% of
subjects during alendronate and denosumab treatment,
respectively. The only serious adverse event in more than
one subject was osteoarthritis, which was reported for three
(1.3%) subjects during denosumab treatment. None of the
serious adverse events was considered related to study
treatment. No deaths, osteonecrosis of the jaw, or atypical
femoral fractures were reported.
Discussion
In this study, postmenopausal women who received
subcutaneous injections of denosumab every 6 months
had significantly better adherence, compliance, and persis-
tence than women who self-administered alendronate orally
once weekly. Non-adherence and non-persistence in the
first year favored denosumab slightly more in the present
analysis than in the prior report [21] because one subject
had missing information at the time of the prior analysis.
Non-adherence, non-compliance, and non-persistence
rates for alendronate-treated subjects were higher after
crossover from denosumab; the rates were lower for
denosumab-treated subjects after crossover from alendro-
nate. These observations suggest there may be a treatment
sequence effect: transitioning from biannual to weekly
administration may have been more difficult to follow than
the converse, an observation that has been noted elsewhere
[24].
The BMQ survey results provided insights into subjects'
impressions of denosumab and alendronate. In each
treatment year, subjects felt the therapy was necessary for
their osteoporosis, regardless of mode of administration.
Even though subjects believed in the necessity of treatment,
they were not fully adherent to either treatment, although
more so with alendronate. Subjects were significantly less
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faction with alendronate or
denosumab at the end of the
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from the last measurements of
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Osteoporos Int (2012) 23:317–326 323concerned about the potential for adverse consequences
with denosumab administration than with alendronate
administration, but only after crossover, when they had
experienced both forms of treatment administration. Of the
subjects who expressed a preference for either therapy at
the end of study, more than 90% said they preferred the
injectable therapy over the tablets, and they would prefer
the injections for long-term treatment. Subject belief and
preference scores at each visit also tended to favor
denosumab, and they generally improved more during
denosumab treatment than during alendronate treatment.
The administration route for denosumab is likely to
influence patient adherence to treatment. The injectable
formulation of denosumab requires subcutaneous adminis-
tration by healthcare professionals, giving them a greater
role in ensuring patients adhere to treatment. It also
provides healthcare professionals with direct evidence of
patient adherence to treatment—and an opportunity to
communicate with the patient about the importance of not
missing scheduled treatments—rather than relying on
patient recall about their treatment adherence.
This study used an open-label, crossover design to assess
adherence and patient-reported outcomes. Two double-blind
studies involving denosumab and alendronate had previ-
ously analyzed patient preference and satisfaction data [11];
however, queries were restricted to the mode of adminis-
tration (injection vs tablet) and dosing frequency (once
weekly vs every 6 months) because subjects were not
informed of their treatment assignment. In the current
evaluation, it was important for subjects to know what
treatment they had received to evaluate their overall
satisfaction with treatment in a situation that mimicked
routine clinical practice to the extent possible.
Follow-up visits with bisphosphonate treatment typically
occur annually; however, visits in this study occurred every
6 months, which could have enhanced adherence. Addi-
tionally, adherence to weekly alendronate treatment re-
quired subjects to take at least 80% of the tablets, including
two of four doses (50%) in the final month; in contrast,
denosumab adherence required administration of 100% of
the doses, possibly biasing against denosumab for adherence.
If adherence to alendronate treatment in this study had
required administration of 100% of doses with four doses in
the final month, the rates of alendronate adherence would
have been substantially lower (18.5% in the first year and
11.3% after crossover).
Study definitions for adherence were selected to focus on
intake of study medication and not clinical benefit to the
subject. Oral alendronate treatment is approved for clinical
use in once-daily and once-weekly regimens, based on
evidence of the clinical benefits of these dosing regimens.
Despite evidence that alendronate remains in the bone
matrix for many years and is gradually released as bone is
resorbed [25], the magnitude and duration of this effect is
uncertain. It has been reported that stopping alendronate
treatment after 4 to 5 years results in a significant increase
in clinical vertebral fractures, but a residual clinical efficacy
for nonvertebral fractures [26]. It has also been reported
that patients who had discontinued bisphosphonate treat-
ment in the previous 6 months had similar fracture risks as
patients who discontinued more distantly and as patients
who just started treatment, suggesting there is little residual
effect on fracture risk reduction after stopping bisphosph-
onates [27]. Thus, although it is possible that subjects who
were non-persistent after receiving alendronate for at least
6 months experienced a carry-over effect for the subsequent
6 months, these effects may not necessarily translate to
clinical benefits for the subject.
Conceptual models have documented the relationship
between non-adherence and cost-effectiveness or value to the
healthcare system [4, 28]. An economic model of the DAPS
results that were reported after the first year concluded,
“Denosumab is a cost-effective alternative to oral osteoporo-
sis treatments, particularly for patients at high risk of fracture
and low expected adherence to oral treatments” [29].
The rate of alendronate non-adherence in this study
(23% in the first year) was lower than in other retrospective
observational reports (33% to 50% in the first year) that
also used the 80% threshold for alendronate adherence [1,
2, 7]. One possible reason for this difference was that
subjects in this study knew that their adherence was being
monitored. Additionally, they knew they would switch
treatment at the crossover, and their BMD was being
monitored, each of which may enhance bisphosphonate
treatment adherence [2]. Other observational studies have
reported even higher rates of bisphosphonate non-
adherence (50% to 80%) with longer follow-up (1.7 to
2.0 years) [2, 3, 5, 6]. Thus, the use of 1-year treatment
periods in this study limits the conclusions that can be made
about long-term compliance with either treatment. Another
potential study limitation was that the study sponsor
provided alendronate and denosumab to the subjects, which
removed any influence of treatment cost on adherence. The
study was conducted at centers in North America (USA and
Canada), and caution is warranted in the extrapolation of
these results in other regions.
Consistent with other denosumab studies [18, 19], both
treatments were well tolerated, and adverse events were
similar between groups in this study. Also consistent with
those prior studies, exploratory analyses from this study
indicated that subjects who crossed over from alendronate
to denosumab continued to have increases in BMD and
reduction of bone turnover markers in the second year.
Subjects who transitioned from denosumab to alendronate
treatment had BMD that remained stabilized from the
increases observed while on denosumab and bone turnover
324 Osteoporos Int (2012) 23:317–326marker levels that increased slightly. This is the first report
showing BMD and bone turnover marker levels for subjects
transitioning from denosumab to alendronate.
In summary, this study showed that postmenopausal
women with low BMD who received alendronate followed
by denosumab, or denosumab followed by alendronate,
preferred treatment with subcutaneous injections of deno-
sumab every 6 months. Increased preference may influence
persistence and adherence with therapy, important charac-
teristics in treatment of a chronic condition that requires
long-term treatment.
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